Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature (Q37633122)

21 August 2017

1 reference

title

Inhibition of vascular endothelial growth factor receptor signaling in angiogenic tumor vasculature (English)

1 reference

21 August 2017

0 references

Marina V Backer

1 reference

21 August 2017

Carl V Hamby

series ordinal

1 reference

21 August 2017

Joseph M Backer

series ordinal

1 reference

21 August 2017

publication date

1 January 2009

1 reference

21 August 2017

1 reference

21 August 2017

1 reference

21 August 2017

page(s)

1-27

1 reference

Functionally active VEGF fusion proteins

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Shiga-like toxin-VEGF fusion proteins are selectively cytotoxic to endothelial cells overexpressing VEGFR-2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Humanized docking system for assembly of targeting drug delivery complexes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Modes of resistance to anti-angiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Interaction of vasculotropin/vascular endothelial cell growth factor with human umbilical vein endothelial cells: Binding, internalization, degradation, and biological effects

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

The RNA-N-glycosidase activity of Shiga-like toxin I: Kinetic parameters of the native and activated toxin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Aflibercept (AVE0005): an alternative strategy for inhibiting tumour angiogenesis by vascular endothelial growth factors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Regulation of VEGF/VPF expression in tumor cells: consequences for tumor growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

DAB389EGF fusion protein therapy of refractory glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Resistance to EGF-R (erbB-1) and VEGF-R modulating agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Molecular mechanisms of the cytotoxicity of ADP-ribosylating toxins

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Apoptosis rate can be accelerated or decelerated by overexpression or reduction of the level of elongation factor-1 alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

VEGF-targeted therapy: mechanisms of anti-tumour activity.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Immunotoxin therapy of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Angiogenesis: new targets for the development of anticancer chemotherapies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Renal effects of anti-angiogenesis therapy: update for the internist

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Cutting off cancer's supply lines

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Whatever happened to immunotoxins? Research, and hope, are still alive

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Different mechanisms of c-Jun NH(2)-terminal kinase-1 (JNK1) activation by ultraviolet-B radiation and by oxidative stressors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Management of hypertension in angiogenesis inhibitor-treated patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Can tyrosine kinase inhibitors be discontinued in patients with metastatic renal cell carcinoma and a complete response to treatment? A multicentre, retrospective analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Predicting benefit from anti-angiogenic agents in malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Recent advances in understanding the pathogenesis of the hemolytic uremic syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Immunotoxins for targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Direct site-specific labeling of the Cys-tag moiety in scVEGF with technetium 99m.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

VEGFs and receptors involved in angiogenesis versus lymphangiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Advances in the structural biology, design and clinical development of VEGF-R kinase inhibitors for the treatment of angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Inhibition of prostate tumor growth and bone remodeling by the vascular targeting agent VEGF121/rGel

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

PATHOGENESIS OF HAEMOLYTIC URAEMIC SYNDROME

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Immunotoxin therapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Design, synthesis and characterization of N9/N7-substituted 6-aminopurines as VEGF-R and EGF-R inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Targeted therapy of cancer using diphtheria toxin-derived immunotoxins.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Mechanisms of angiogenesis and their use in the inhibition of tumor growth and metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Endocytosis from coated pits of Shiga toxin: a glycolipid-binding protein from Shigella dysenteriae 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Acute pharmacodynamic and antivascular effects of the vascular endothelial growth factor signaling inhibitor AZD2171 in Calu-6 human lung tumor xenografts.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Synthesis of quinazolines as tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Ribosome-inactivating proteins: progress and problems.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Biological properties of VEGF/VPF receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Renal dysfunction accounts for the dose limiting toxicity of DT390anti-CD3sFv, a potential new recombinant anti-GVHD immunotoxin

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Tyrosine kinase inhibitors of VEGF receptors: clinical issues and remaining questions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

VEGFs, receptors and angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

A new PET tracer specific for vascular endothelial growth factor receptor 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Site-specifically biotinylated VEGF(121) for near-infrared fluorescence imaging of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

1 reference

7 January 2021

Comparison of ribosome-inactivating proteins in the induction of apoptosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Quantification of infarct size on focal cerebral ischemia model of rats using a simple and economical method

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

Purification and characterization of a Shiga toxin A subunit-CD4 fusion protein cytotoxic to human immunodeficiency virus-infected cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-2660%2809%2967001-2

7 January 2021

10.1016/S0065-2660(09)67001-2

Identifiers

DOI

1 reference

release_muj4uxktbfevrg6xl3xomjio6u

21 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/muj4uxktbfevrg6xl3xomjio6u

24 November 2022

mapped directly with Wikidata item

1 reference